Physician profile
Bryant E Bojewski
NPI 1124009188
$8,664.86
in general payments reported to CMS, 2019-2025
43 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $1,192 · 2021: $1,607 · 2022: $1,256 · 2023: $1,026 · 2024: $1,132 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,161.87 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $720.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $657.21 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $642.49 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $571.44 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $530.49 | 2021-2025 | Qulipta |
| Pfizer INC. | $528.66 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $472.45 | 2019-2024 | Spravato |
| Glaxosmithkline, LLC. | $470.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $339.54 | 2019-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.93 | 2019-2024 | Xifaxan |
| Amgen INC. | $195.68 | 2020-2025 | Repatha, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.28 | 2025 | Caplyta |
| Indivior INC. | $142.30 | 2019-2023 | Sublocade |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Bojewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.